Cargando…
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity
We report an 80-year-old woman with EGFR-mutant lung adenocarcinoma with multiple brain metastases (BMs). All lesions including BM showed a successful resolution after initiating daily 150 mg erlotinib. However, a grade 2 bilirubin-increase developed, and it was necessary to reduce the dose of erlot...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709634/ https://www.ncbi.nlm.nih.gov/pubmed/28943548 http://dx.doi.org/10.2169/internalmedicine.8638-16 |
_version_ | 1783282816657653760 |
---|---|
author | Yamanaka, Yumie Sekine, Akimasa Kato, Terufumi Yamakawa, Hideaki Ikeda, Satoshi Baba, Tomohisa Iwasawa, Tae Okudela, Koji Ogura, Takashi |
author_facet | Yamanaka, Yumie Sekine, Akimasa Kato, Terufumi Yamakawa, Hideaki Ikeda, Satoshi Baba, Tomohisa Iwasawa, Tae Okudela, Koji Ogura, Takashi |
author_sort | Yamanaka, Yumie |
collection | PubMed |
description | We report an 80-year-old woman with EGFR-mutant lung adenocarcinoma with multiple brain metastases (BMs). All lesions including BM showed a successful resolution after initiating daily 150 mg erlotinib. However, a grade 2 bilirubin-increase developed, and it was necessary to reduce the dose of erlotinib to 50 mg every other day, which aggravated BM. Switching erlotinib to afatinib led to the resolution of BM without an increase in the bilirubin level. Our results indicate that afatinib is an important treatment option when erlotinib-induced hepatotoxicity develops, regardless of the patients' age. Particularly in those patients with BM, switching to afatinib may be preferable to reducing the dose of erlotinib. |
format | Online Article Text |
id | pubmed-5709634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-57096342017-12-04 Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity Yamanaka, Yumie Sekine, Akimasa Kato, Terufumi Yamakawa, Hideaki Ikeda, Satoshi Baba, Tomohisa Iwasawa, Tae Okudela, Koji Ogura, Takashi Intern Med Case Report We report an 80-year-old woman with EGFR-mutant lung adenocarcinoma with multiple brain metastases (BMs). All lesions including BM showed a successful resolution after initiating daily 150 mg erlotinib. However, a grade 2 bilirubin-increase developed, and it was necessary to reduce the dose of erlotinib to 50 mg every other day, which aggravated BM. Switching erlotinib to afatinib led to the resolution of BM without an increase in the bilirubin level. Our results indicate that afatinib is an important treatment option when erlotinib-induced hepatotoxicity develops, regardless of the patients' age. Particularly in those patients with BM, switching to afatinib may be preferable to reducing the dose of erlotinib. The Japanese Society of Internal Medicine 2017-09-25 2017-11-01 /pmc/articles/PMC5709634/ /pubmed/28943548 http://dx.doi.org/10.2169/internalmedicine.8638-16 Text en Copyright © 2017 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Yamanaka, Yumie Sekine, Akimasa Kato, Terufumi Yamakawa, Hideaki Ikeda, Satoshi Baba, Tomohisa Iwasawa, Tae Okudela, Koji Ogura, Takashi Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity |
title | Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity |
title_full | Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity |
title_fullStr | Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity |
title_full_unstemmed | Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity |
title_short | Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity |
title_sort | afatinib therapy for brain metastases aggravated by a reduction in the dose of erlotinib due to the development of hepatotoxicity |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709634/ https://www.ncbi.nlm.nih.gov/pubmed/28943548 http://dx.doi.org/10.2169/internalmedicine.8638-16 |
work_keys_str_mv | AT yamanakayumie afatinibtherapyforbrainmetastasesaggravatedbyareductioninthedoseoferlotinibduetothedevelopmentofhepatotoxicity AT sekineakimasa afatinibtherapyforbrainmetastasesaggravatedbyareductioninthedoseoferlotinibduetothedevelopmentofhepatotoxicity AT katoterufumi afatinibtherapyforbrainmetastasesaggravatedbyareductioninthedoseoferlotinibduetothedevelopmentofhepatotoxicity AT yamakawahideaki afatinibtherapyforbrainmetastasesaggravatedbyareductioninthedoseoferlotinibduetothedevelopmentofhepatotoxicity AT ikedasatoshi afatinibtherapyforbrainmetastasesaggravatedbyareductioninthedoseoferlotinibduetothedevelopmentofhepatotoxicity AT babatomohisa afatinibtherapyforbrainmetastasesaggravatedbyareductioninthedoseoferlotinibduetothedevelopmentofhepatotoxicity AT iwasawatae afatinibtherapyforbrainmetastasesaggravatedbyareductioninthedoseoferlotinibduetothedevelopmentofhepatotoxicity AT okudelakoji afatinibtherapyforbrainmetastasesaggravatedbyareductioninthedoseoferlotinibduetothedevelopmentofhepatotoxicity AT oguratakashi afatinibtherapyforbrainmetastasesaggravatedbyareductioninthedoseoferlotinibduetothedevelopmentofhepatotoxicity |